
TWST Stock Forecast & Price Target
TWST Analyst Ratings
Bulls say
Twist Bioscience is at the forefront of the rapidly expanding synthetic biology industry, with their innovative and efficient DNA synthesis platform positioning them for long-term growth. The recent momentum driven by AI drug discovery is a strong indication of the company's potential for continued expansion and success in their core NGS segment. Despite a strong YTD performance, the stock still remains attractive, with upside potential from multiple avenues such as expanding manufacturing capacity, possible acquisitions, and surprise product launches. The potential for continued growth, profitability, and operating leverage make Twist Bioscience a compelling investment opportunity in the life science tools sector, with a BUY rating and a price target of $60 based on a SOTP valuation method.
Bears say
Twist Bioscience is currently experiencing strong revenue growth and beat earnings expectations in F2Q26, positioning them for continued success in the near future. However, there are risks related to their margins and operating leverage, and any slowdown in end-market growth for NGS products or unexpected competition could impact their growth potential. Additionally, while Twist has seen growth in all geographic regions, they are heavily dependent on the Americas for revenue, which could pose a risk in terms of diversification.
This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares